

CHIMERIX INC  
Form 8-K  
September 29, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**September 26, 2014**

Date of Report (Date of earliest event reported)

**Chimerix, Inc.**



**Item 7.01 Regulation FD Disclosure.**

On October 11, 2014, Chimerix, Inc. (the “*Company*”) is scheduled to present at ID Week 2014 in Philadelphia, PA, in a presentation titled “Preliminary safety results and antiviral activity from the open-label pilot portion of a Phase 3 study to evaluate Brincidofovir (BCV) for the treatment of adenovirus (ADV) infection”.

An abstract summarizing the Company’s scheduled presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Forward-Looking Statements**

Statements contained in, or incorporated by reference into, this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company’s filings with the Securities and Exchange Commission, including without limitation the Company’s most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Chimerix, Inc. presentation abstract.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Chimerix, Inc.**

Dated: September 26, 2014

By: /s/ Timothy W. Trost  
Timothy W. Trost  
Senior Vice President,  
Chief Financial Officer  
and Corporate  
Secretary

**INDEX TO EXHIBITS**

Exhibit No.	Description
99.1	Chimerix, Inc. presentation abstract.